Role of Multidrug Resistance 3 Deficiency in Pediatric and Adult Liver Disease: One Gene for Three Diseases

 

 Buy Article Permissions and Reprints

ABSTRACT

Class III multidrug resistance P-glycoproteins, mdr2 in mice and MDR3 in humans, are canalicular phospholipid translocators involved in biliary phospholipid (phosphatidylcholine) excretion. The role of an MDR3 gene defect in liver disease was initially suspected in a subtype of progressive familial intrahepatic cholestasis called PFIC3. Several MDR3 mutations have been identified in children with PFIC3 and are associated with a low level of phospholipids in bile, leading to a high biliary cholesterol saturation index. Mutations leading to a truncated protein are associated with an absence of canalicular MDR3 protein. The phenotypic spectrum of PFIC3 ranges from neonatal cholestasis to cirrhosis in young adults. There is now strong evidence that in addition to PFIC3, an MDR3 defect can be involved in intrahepatic cholestasis of pregnancy and in cholesterol gallstone disease. Therefore, at least three human liver diseases are due to a single gene deficiency. Patients with PFIC3 due to MDR3 deficiency may benefit from ursodeoxycholic acid therapy and could be good candidates for cell therapy in the future.

REFERENCES

• 1 Deleuze J F, Jacquemin E, Dubuisson C. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis.  Hepatology . 1996;  23 904-908
  CrossrefPubMedGoogle Scholar
• 2 Clayton R J, Iber F L, Ruebner B H. Byler disease: fatal familial intrahepatic cholestasis in an Amish kindred.  Am J Dis Child . 1969;  117 112-124
  PubMedGoogle Scholar
• 3 Linarelli L G, Williams C N, Phillips M J. Byler's disease: fatal intrahepatic cholestasis.  J Pediatr . 1972;  81 484-492
  PubMedGoogle Scholar
• 4 Whitington P F, Freese D K, Alonso E M. Clinical and biochemical findings in progressive familial intrahepatic cholestasis.  J Pediatr Gastroenterol Nutr . 1994;  18 134-141
  PubMedGoogle Scholar
• 5 Williams C N, Kaye R, Baker L. Progressive familial cholestatic cirrhosis and bile acid metabolism.  J Pediatr . 1972;  81 493-500
  PubMedGoogle Scholar
• 6 Jacquemin E, Dumont M, Bernard O. Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease).  Eur J Pediatr . 1994;  153 424-428
  CrossrefPubMedGoogle Scholar
• 7 Bull L N, Carlton V EH, Stricker N L. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity.  Hepatology . 1997;  26 155-164
  CrossrefPubMedGoogle Scholar
• 8 Jacquemin E, Setchell K DR, O'Connell N C. A new cause of progressive intrahepatic cholestasis: 3β-Hydroxy-C₂₇-steroid dehydrogenase/isomerase deficiency.  J Pediatr . 1994;  125 379-384
  PubMedGoogle Scholar
• 9 Balistreri W F. Inborn errors of bile acid biosynthesis and transport: novel form of metabolic liver diseases.  Gastroenterol Clin North Am . 1999;  28 145-172
  CrossrefPubMedGoogle Scholar
• 10 Trauner M, Meier P J, Boyer J L. Molecular pathogenesis of cholestasis.  N Engl J Med . 1998;  339 1217-1227
  CrossrefPubMedGoogle Scholar
• 11 Bezerra J A, Balistreri W F. Intrahepatic cholestasis: order out of chaos.  Gastroenterology . 1999;  117 1496-1498
  PubMedGoogle Scholar
• 12 Jacquemin E, Hadchouel M. Genetic basis of progressive familial intrahepatic cholestasis.  J Hepatol . 1999;  31 377-381
  CrossrefPubMedGoogle Scholar
• 13 Bull L N, van Eijk J T M, Pawlikowska L. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis.  Nat Genet . 1998;  18 219-224
  CrossrefPubMedGoogle Scholar
• 14 Strautnieks S S, Bull L N, Knisely A S. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis.  Nat Genet . 1998;  20 233-238
  CrossrefPubMedGoogle Scholar
• 15 Jansen P LM, Strautnieks S S, Jacquemin E. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis.  Gastroenterology . 1999;  117 1370-1379
  CrossrefPubMedGoogle Scholar
• 16 Maggiore G, Bernard O, Riely C. Normal serum gamma-glutamyl-transpeptidase activity identifies groups of infants with idiopathic cholestasis with poor prognosis.  J Pediatr . 1987;  111 251-252
  PubMedGoogle Scholar
• 17 Alonso E M, Snover D C, Montag A. Histologic pathology of the liver in progressive familial intrahepatic cholestasis.  J Pediatr Gastroenterol Nutr . 1994;  18 128-133
  CrossrefPubMedGoogle Scholar
• 18 Maggiore G, Bernard O, Hadchouel M. Diagnostic value of serum γ-glutamyl transpeptidase activity in liver diseases in children.  J Pediatr Gastroenterol Nutr . 1991;  12 21-26
  PubMedGoogle Scholar
• 19 Smit J JM, Shinkel A H, Oude Elferink P J R. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.  Cell . 1993;  75 451-462
  CrossrefPubMedGoogle Scholar
• 20 Reutz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene.  Cell . 1994;  77 1071-1081
  CrossrefPubMedGoogle Scholar
• 21 Smit J JM, Shinkel A H, Mol C A M A. Tissue distribution of the human MDR3 P-glycoprotein.  Lab Invest . 1994;  71 638-649
  PubMedGoogle Scholar
• 22 Smith A J, de Vree M L J, Ottenhoff R. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in mdr2 (-/-) mice.  Hepatology . 1998;  28 530-536
  CrossrefPubMedGoogle Scholar
• 23 de Vree M L J, Jacquemin E, Sturm E. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis.  Proc Natl Acad Sci U S A . 1998;  95 282-287
  CrossrefPubMedGoogle Scholar
• 24 Jacquemin E, Cresteil D, Manouvrier S. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy.  Lancet . 1999;  353 210-211
  CrossrefPubMedGoogle Scholar
• 25 Jacquemin E, de Vree L M J, Cresteil D. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.  Gastroenterology . 2001;  120 1448-1458
  CrossrefPubMedGoogle Scholar
• 26 Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis.  Gastroenterology . 2001;  120 1459-1467
  CrossrefPubMedGoogle Scholar
• 27 Mauad T H, van Nieuwkerk M C, Digemans K P. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis.  Am J Pathol . 1994;  145 1237-1245
  PubMedGoogle Scholar
• 28 van Nieuwkerk J M C, Oude Elferink P J R, Groen A K. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 p-glycoprotein gene.  Gastroenterology . 1996;  111 165-171
  PubMedGoogle Scholar
• 29 Elferink R P, Ottenhoff R, van Marle J. Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse.  J Clin Invest . 1998;  102 1749-1757
  PubMedGoogle Scholar
• 30 Hamosh A, Rosenstein B J, Cutting G R. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells.  Hum Mol Genet . 1992;  1 542-544
  CrossrefPubMedGoogle Scholar
• 31 Gottesman M M, Hrycyna C A, Schoenlein P V. Genetic analysis of the multidrug transporter.  Annu Rev Genet . 1995;  29 607-649
  CrossrefPubMedGoogle Scholar
• 32 Beaudet L, Urbatsch I L, Gros P. Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphatase activity.  Biochemistry . 1998;  37 9073-9082
  CrossrefPubMedGoogle Scholar
• 33 Urbatsch I L, Beaudet L, Carrier I. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites.  Biochemistry . 1998;  37 4592-4602
  CrossrefPubMedGoogle Scholar
• 34 Loo T W, Clarke D M. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein.  Biochemistry . 1994;  33 14049-14057
  CrossrefPubMedGoogle Scholar
• 35 Loo T W, Clarke D M. Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12.  J Biol Chem . 1997;  272 20986-20989
  CrossrefPubMedGoogle Scholar
• 36 Toh S, Wada M, Uchiumi T. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome.  Am J Hum Genet . 1999;  64 739-746
  CrossrefPubMedGoogle Scholar
• 37 Dixon P H, Weerasekera N, Linton K J. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking.  Hum Mol Genet . 2000;  9 1209-1217
  CrossrefPubMedGoogle Scholar
• 38 Riordan J R. Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein.  Am J Hum Genet . 1999;  64 1499-1504
  CrossrefPubMedGoogle Scholar
• 39 Hoffmeyer S, Burk O, von Richter O. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.  Proc Natl Acad Sci U S A . 2000;  97 3473-3478
  CrossrefPubMedGoogle Scholar
• 40 Forbes J R, Cox D W. Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant?.  Am J Hum Genet . 1998;  63 1663-1674
  CrossrefPubMedGoogle Scholar
• 41 Ortiz D, Arias I M. MDR3 mutations: a glimpse into Pandora's box and the future of canalicular pathophysiology.  Gastroenterology . 2001;  120 1549-1552
  CrossrefPubMedGoogle Scholar
• 42 Jacquemin E, Hermans D, Myara A. Ursodeoxycholic therapy in pediatric patients with progressive familial intrahepatic cholestasis.  Hepatology . 1997;  25 519-523
  CrossrefPubMedGoogle Scholar
• 43 Gupta S, Stravitz T, Pandak W M. Regulation of multidrug resistance 2 P-glycoprotein expression by bile salts in rats and in primary cultures of rat hepatocytes.  Hepatology . 2000;  32 341-347
  CrossrefPubMedGoogle Scholar
• 44 Lincke C R, Smit J JM, van Der Velde-Koerts T. Structure of the human MDR3 gene and physical mapping of the human MDR locus.  J Biol Chem . 1991;  266 5303-5310
  PubMedGoogle Scholar
• 45 Bacq Y, Sapey T, Bréchot M C. Intrahepatic cholestasis of pregnancy: a French prospective study.  Hepatology . 1997;  26 358-364
  CrossrefPubMedGoogle Scholar
• 46 Holzbach R T, Sivak D A, Braun W E. Familial recurrent intrahepatic cholestasis of pregnancy: a genetic study providing evidence for transmission of a sex-limited, dominant trait.  Gastroenterology . 1983;  85 175-179
  PubMedGoogle Scholar
• 47 Hooiveld G E J J, Vos T A, Scheffer G L. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats.  Gastroenterology . 1999;  117 678-687
  PubMedGoogle Scholar
• 48 Smith A J, van Helvoort A, van Meer G. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping.  J Biol Chem . 2000;  275 23530-23539
  CrossrefPubMedGoogle Scholar
• 49 De Pagter G F A, Van Berge Henegouwen P G, Ten Bokkel Huinink A J. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives?.  Gastroenterology . 1976;  71 202-207
  PubMedGoogle Scholar
• 50 Brenard R, Geubel A P, Benhamou J P. Benign recurrent intrahepatic cholestasis. A report of 26 cases.  J Clin Gastroenterol . 1989;  11 546-551
  CrossrefPubMedGoogle Scholar
• 51 Jacquemin E, Lykavieris P, Chaoui N. Transient neonatal cholestasis: origin and outcome.  J Pediatr . 1998;  133 563-567
  PubMedGoogle Scholar
• 52 Mazella G, Rizzo N, Azzarolli F. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.  Hepatology . 2001;  33 504-508
  CrossrefPubMedGoogle Scholar
• 53 Vos T A, Hooiveld G E J J, Koning H. Up-regulation of the multidrugresistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver.  Hepatology . 1998;  28 1637-1644
  CrossrefPubMedGoogle Scholar
• 54 van Helvoort A, Smith J A, Sprong H. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.  Cell . 1996;  87 507-517
  CrossrefPubMedGoogle Scholar
• 55 Lallemand J Y, Stoven V, Annereau J P. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis?.  Lancet . 1997;  350 711-712
  PubMedGoogle Scholar
• 56 Altschuler E L. Azithromycin, the multidrug-resistant protein and cystic fibrosis.  Lancet . 1998;  351 1286
  PubMedGoogle Scholar
• 57 de Vree M L J, Ottenhoff R, Bosma P J. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis.  Gastroenterology . 2000;  119 1720-1730
  PubMedGoogle Scholar